Tonix Pharmaceuticals stock halted ahead of FDA approval news
On Friday, Canaccord Genuity maintained a Buy rating with a $366.00 price target on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). Following Alnylam's TTR investor day, the firm expressed strong confidence in the potential of Amvuttra for the treatment of ATTR-CM, a heart condition. The event provided insights into Alnylam's launch strategies and market positioning for the product.
Alnylam Pharmaceuticals has revised its patient prevalence estimate for ATTR-CM to over 300,000, an increase from the previously stated range of 200,000 to 300,000. This update indicates a larger potential market for Amvuttra. The company's discussion on the dynamics between Medicare Part B and Part D was also highlighted as informative, addressing investor queries regarding this aspect of drug distribution and reimbursement.
The cost of Amvuttra remains uncertain, but the analyst anticipates the pricing to align roughly with that of the branded drug tafamidis. Further clarity on the pricing is expected to come soon, as Alnylam recently announced the submission of Amvuttra's supplemental New Drug Application (sNDA) to the FDA, utilizing a priority review voucher. This could lead to potential approval and pricing details by the second quarter of 2025.
Canaccord Genuity's reiteration of the Buy rating underscores their optimism about Alnylam's commercial prospects for Amvuttra. The company's strategic preparations for the product launch and the updated prevalence estimate suggest a strong market opportunity, pending FDA approval.
In other recent news, Alnylam Pharmaceuticals has maintained positive ratings from several investment firms, including TD Cowen, BMO Capital, Piper Sandler, Oppenheimer, and Citi. These ratings follow the submission of a New Drug Application (NDA) for vutrisiran, a treatment for ATTR-CM, a condition affecting the heart.
Alnylam's Q2 earnings report exceeded expectations in both revenue and profit, leading to an updated 2024 revenue guidance of between $1.575 billion and $1.65 billion. This success is attributed to the growth of its TTR franchise and a milestone payment from a licensing agreement with Regeneron (NASDAQ:REGN).
The company is also preparing for the potential market entry of vutrisiran by expanding its field team, expected to cover approximately 3,700 healthcare providers, representing nearly 95% of the patient population affected by ATTR-CM. Alnylam's commercial strategy for the launch of Amvuttra in treating ATTR-CM received positive feedback from BofA Securities.
In collaboration with BridgeBio Pharma (NASDAQ:BBIO), Alnylam presented a new post hoc analysis of recurrent all-cause mortality and cardiovascular-related hospitalization events, highlighting its ongoing efforts to address unmet medical needs in the treatment of ATTR-CM. The company plans to establish Amvuttra as the first-line treatment of choice for ATTR-CM, leveraging promising HELIOS-B trial data and a more convenient dosing regimen.
InvestingPro Insights
Alnylam Pharmaceuticals' (NASDAQ:ALNY) strong market position and growth potential, as highlighted in the article, are further supported by recent financial data and analyst insights from InvestingPro. The company's impressive revenue growth of 89.46% over the last twelve months, with a notable 107% increase in the most recent quarter, aligns with the optimistic outlook for Amvuttra's market potential.
InvestingPro Tips reveal that 10 analysts have revised their earnings upwards for the upcoming period, indicating growing confidence in Alnylam's financial prospects. This positive sentiment is reflected in the stock's performance, with a 66.02% price return over the past year and trading near its 52-week high.
The company's gross profit margin of 87% is described as "impressive" by InvestingPro, suggesting efficient cost management and potentially strong pricing power for products like Amvuttra. However, investors should note that analysts do not anticipate the company to be profitable this year, which is consistent with the article's focus on future market opportunities rather than immediate profitability.
For readers interested in a more comprehensive analysis, InvestingPro offers 13 additional tips for Alnylam Pharmaceuticals, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.